TCR2 Therapeutics Inc., a Cambridge, Mass.-based immunotherapy developer targeting solid tumors with an approach to T-cell therapies that its execs say will improve safety and durability, has landed a $44.5 million series A financing expected to carry its anticancer aspirations into the clinic by the end of 2018.